Special Guest · 8:00–8:15 AM PT
?
Special guest
Guest speaker (8:00–8:15 PT): Patrick Brennan & Beth Perkins — AdvaMed. AdvaMed Accel® advocates for regulatory and payment policies supporting small/emerging medtech companies and capital formation. advamed.org/advamed-accel/ | themedtechconference.com
Pitches · 8:15–9:30 AM PT
RefloDx, Inc.
Gregory Critchfield, CEO · gregc.critchfield@gmail.com
Round
$2,000,000 Post-money SAFE @ SAFE note with postmoney cap is $8,000,000
Closed
$1,200,000
FDA milestone
Ability to detect bolus material in esophagus has been published vs. videofluoroscopy
FDA timeline
Submission on or before Q1 2028: Following rigorous blinded clinical validation compared to predicate device ; approval anticipated Q3 2028
Other groups in round
High net worth individuals (n=3), TAAC 7, Park City Angels,Salt Lake City Angels, state of Utah Nucleus Fund, Wild Tree Ventures
DD package
Trans Atlantic Angel Competition #7 DD available
Traction: We are pre-commercial
CoraVie Medical
Aimee Garza, CEO · aimee.garza@coraviemedical.com
CoraVie Medical is revolutionizing hypertension management with an implantable, ultrasound-based blood pressure and cardiovascular monitoring platform - providing earlier access to actionable blood pressure and cardiovascular insights, enabling faster clinical decisions, improved therapy optimization, and reduced risk of devastating events such as stroke.
Round
1,000,000 Bridge round; in parallel we kicked off a $7M Priced Equity Seed round and are seeking lead (pitch deck references the $7M seed round); Convertible Note @ Bridge Terms: 1M raise, 8% interest, 30% discount, 9M pre Convertible Note.
Closed
$0 (Bridge kicked off in March 2026) in parallel to a Priced Equity Seed round for which we are seeking a lead.
FDA milestone
CoraVie has FDA Breakthough Device Designation (BDD) and pre-sub confirm an option for DeNovo Regulatory path. We have completed several pre-clinical animal studies demonstrating repeatable accurate BP and are now preparing to build device for first-in-human evaluations. With the right strategic partner we will pursue PMA. We have also completed a reimbursement landscape and are following known successful precedents in implantable monitoring.
FDA timeline
36-48 months
Other groups in round
Past seed round investors include Gopher Angels, Golden Seeds, 701 Angels, and Keiretsu NW
DD package
DD reports from prior round lead and groups that have invested in CoraVie, including Gopher Angels, Golden Seeds, Keiretsu NW;
Traction: Demonstration of repeatable accurate BP in animals, published poster abstract at AHA-Hypertension; MVP Concept review significantly reduced technical risk; 8 issued patents with broad claims awarded, several others pending; Accepted to Medtech3.0 MNCubator and partnered with Medtronic (several other past accelerators);
What they're looking for: We are always looking for KOL advisors and partners that can help us get our product to the market;
Kato Medical Inc
Albert Hill, CEO · ahill@katomed.ai
FasTrack™ is an AI-powered surgical navigation platform that converts 2D fluoroscopy and diagnostic CTs into precise 3D maps for real-time surgical guidance.
Round
$5M Post-money SAFE @ 27M
Closed
$1.5M
FDA milestone
Completed FDA Validation Testing
FDA timeline
April 2026 - submission - July 2026 - Approval
Other groups in round
Reefhaven Ventures, Kyocera Corporate Venture Fund
DD package
No
Traction: Commercialization partner investment, surgeon KOL investment, distributor channel investment, 10+ surgeon evaluators
What they're looking for: Distributor references, KOL/Surgeon introductions